Cargando…

698. 8 Years of Infective Endocarditis in Intravenous and Non-Intravenous Drug Users a Single Center Experience

BACKGROUND: Despite advances in diagnosis and management, infective endocarditis (IE) is associated with considerable morbidity and mortality. Given the emergence of drug- resistant organisms, it is unclear whether this has impacted the characteristics and outcomes of IE among intravenous drug users...

Descripción completa

Detalles Bibliográficos
Autores principales: Alpizar-Rivas, Rodolfo M, Balda, Javier, Elarabi, Salwa, Jaber, Bertrand, Nader, Claudia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7778004/
http://dx.doi.org/10.1093/ofid/ofaa439.890
_version_ 1783631036064727040
author Alpizar-Rivas, Rodolfo M
Balda, Javier
Elarabi, Salwa
Jaber, Bertrand
Nader, Claudia
author_facet Alpizar-Rivas, Rodolfo M
Balda, Javier
Elarabi, Salwa
Jaber, Bertrand
Nader, Claudia
author_sort Alpizar-Rivas, Rodolfo M
collection PubMed
description BACKGROUND: Despite advances in diagnosis and management, infective endocarditis (IE) is associated with considerable morbidity and mortality. Given the emergence of drug- resistant organisms, it is unclear whether this has impacted the characteristics and outcomes of IE among intravenous drug users (IDUs) and non-IDUs. METHODS: We conducted a single center retrospective cohort study. 306 records of hospitalized adults diagnose with IE by ICD-9/ICD-10 codes were identified from 2011 to 2018. 244 patients met criteria. IRB approval was obtained. The baseline demographic, microbiologic, echocardiographic variables and outcomes were extracted from the chart, and compared between IDUs and non-IDUs. RESULTS: 112 (45.9%) patients were IDUs and significantly younger (mean age 36 vs. 64, p< 0.001). Both methicillin-sensitive (44.6% vs. 23.5%, p< 0.001) and methicillin-resistant (29.5% vs. 13.6%, p= 0.002) Staphylococcus aureus associated IE were more prevalent in IDUs compared to non-IDUs. Streptococcus species (22.7% vs 11.6%, p=0.02), excluding Enterococcus species, and coagulase-negative Staphylococcus (12.1% vs 1.8%, p=0.002) were significantly more prevalent in non-IDUs. IE in IDUs were more likely to have tricuspid valve vegetations (56.3% vs. 13.6%, p< 0.001), whereas non-IDUs were more likely to have mitral valve (39.4% vs. 25%, p=0.02) and aortic valve vegetations (46.2% vs. 15.2%, p< 0.001). 19% of patients with IE underwent valve replacement within 6 months, and 17% died within 90 days. A multivariable model that included age, gender, and IDU status, age was the only variable that remained independently associated with 90-day mortality (adjusted OR 1.031; 95% CI 1.006, 1.057; p< 0.01). CONCLUSION: In this single-center experience, we found that methicillin-sensitive Staphylococcus aureus was the dominant organism among IDUs and non-IDUs. We also found that methicillin-resistant Staphylococcus aureus was significantly more prevalent among IDUs with IE. Provably related to an increase prevalence of colonization with resistant organisms in the community. Despite the shift in prevalence of methicillin-resistant Staphylococcus aureus among IDUs, there was no increased 90-day mortality risk after adjustment for age and gender. DISCLOSURES: All Authors: No reported disclosures
format Online
Article
Text
id pubmed-7778004
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-77780042021-01-07 698. 8 Years of Infective Endocarditis in Intravenous and Non-Intravenous Drug Users a Single Center Experience Alpizar-Rivas, Rodolfo M Balda, Javier Elarabi, Salwa Jaber, Bertrand Nader, Claudia Open Forum Infect Dis Poster Abstracts BACKGROUND: Despite advances in diagnosis and management, infective endocarditis (IE) is associated with considerable morbidity and mortality. Given the emergence of drug- resistant organisms, it is unclear whether this has impacted the characteristics and outcomes of IE among intravenous drug users (IDUs) and non-IDUs. METHODS: We conducted a single center retrospective cohort study. 306 records of hospitalized adults diagnose with IE by ICD-9/ICD-10 codes were identified from 2011 to 2018. 244 patients met criteria. IRB approval was obtained. The baseline demographic, microbiologic, echocardiographic variables and outcomes were extracted from the chart, and compared between IDUs and non-IDUs. RESULTS: 112 (45.9%) patients were IDUs and significantly younger (mean age 36 vs. 64, p< 0.001). Both methicillin-sensitive (44.6% vs. 23.5%, p< 0.001) and methicillin-resistant (29.5% vs. 13.6%, p= 0.002) Staphylococcus aureus associated IE were more prevalent in IDUs compared to non-IDUs. Streptococcus species (22.7% vs 11.6%, p=0.02), excluding Enterococcus species, and coagulase-negative Staphylococcus (12.1% vs 1.8%, p=0.002) were significantly more prevalent in non-IDUs. IE in IDUs were more likely to have tricuspid valve vegetations (56.3% vs. 13.6%, p< 0.001), whereas non-IDUs were more likely to have mitral valve (39.4% vs. 25%, p=0.02) and aortic valve vegetations (46.2% vs. 15.2%, p< 0.001). 19% of patients with IE underwent valve replacement within 6 months, and 17% died within 90 days. A multivariable model that included age, gender, and IDU status, age was the only variable that remained independently associated with 90-day mortality (adjusted OR 1.031; 95% CI 1.006, 1.057; p< 0.01). CONCLUSION: In this single-center experience, we found that methicillin-sensitive Staphylococcus aureus was the dominant organism among IDUs and non-IDUs. We also found that methicillin-resistant Staphylococcus aureus was significantly more prevalent among IDUs with IE. Provably related to an increase prevalence of colonization with resistant organisms in the community. Despite the shift in prevalence of methicillin-resistant Staphylococcus aureus among IDUs, there was no increased 90-day mortality risk after adjustment for age and gender. DISCLOSURES: All Authors: No reported disclosures Oxford University Press 2020-12-31 /pmc/articles/PMC7778004/ http://dx.doi.org/10.1093/ofid/ofaa439.890 Text en © The Author 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Poster Abstracts
Alpizar-Rivas, Rodolfo M
Balda, Javier
Elarabi, Salwa
Jaber, Bertrand
Nader, Claudia
698. 8 Years of Infective Endocarditis in Intravenous and Non-Intravenous Drug Users a Single Center Experience
title 698. 8 Years of Infective Endocarditis in Intravenous and Non-Intravenous Drug Users a Single Center Experience
title_full 698. 8 Years of Infective Endocarditis in Intravenous and Non-Intravenous Drug Users a Single Center Experience
title_fullStr 698. 8 Years of Infective Endocarditis in Intravenous and Non-Intravenous Drug Users a Single Center Experience
title_full_unstemmed 698. 8 Years of Infective Endocarditis in Intravenous and Non-Intravenous Drug Users a Single Center Experience
title_short 698. 8 Years of Infective Endocarditis in Intravenous and Non-Intravenous Drug Users a Single Center Experience
title_sort 698. 8 years of infective endocarditis in intravenous and non-intravenous drug users a single center experience
topic Poster Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7778004/
http://dx.doi.org/10.1093/ofid/ofaa439.890
work_keys_str_mv AT alpizarrivasrodolfom 6988yearsofinfectiveendocarditisinintravenousandnonintravenousdrugusersasinglecenterexperience
AT baldajavier 6988yearsofinfectiveendocarditisinintravenousandnonintravenousdrugusersasinglecenterexperience
AT elarabisalwa 6988yearsofinfectiveendocarditisinintravenousandnonintravenousdrugusersasinglecenterexperience
AT jaberbertrand 6988yearsofinfectiveendocarditisinintravenousandnonintravenousdrugusersasinglecenterexperience
AT naderclaudia 6988yearsofinfectiveendocarditisinintravenousandnonintravenousdrugusersasinglecenterexperience